Editor's Note: the "Trending USA Stocks" column tracks the day's top bullish stocks in the USA market, aiding investors in promptly identifying opportunities for potential gains.

22/06/2026 Eastern Time in USA The Dow Jones Industrial Average rose by 0.29%, closing at 51712.71 points; the Nasdaq Composite dropped by 1.32%, closing at 26166.6 points; the S&P 500 Index dropped by 0.37%, closing at 7472.79 points. Sahm has compiled the Top 10 Daily Stock Price Gainers in the USA market.

Getty Images Holdings, Inc. Class A: Overnight gain 90.0%, Surges on Landmark OpenAI Partnership for AI-Powered Content Integration

Getty Images Holdings, Inc. Emerges as Global Visual Content Market Leader Getty Images Holdings, Inc., incorporated in 2012, has established itself as a premier global visual content provider, delivering comprehensive content solutions to clients across all market segments. The company operates a diversified portfolio of platforms including Getty Images, iStock, and Unsplash, serving international clientele through web-based interfaces and API integration services, positioning itself as a dominant marketplace for premium visual content transactions. The corporation has cultivated an extensive content supply network, maintaining strategic partnerships with over 488,000 content contributors and more than 300 premium partners. This robust ecosystem enables comprehensive coverage across news, sports, and entertainment sectors, with the company documenting approximately 160,000 significant events annually and providing in-depth professional editorial coverage. Getty Images Holdings maintains one of the world's largest privately-held photographic archives, housing millions of historical images spanning from the early development of photographic technology to present day. This extensive historical repository provides clients with unparalleled access to archival visual assets, reinforcing the company's market position as a comprehensive visual content solutions provider in the global digital media landscape.

Getty Images Holdings, Inc. Class A (GETY) shares surged following the announcement of a landmark partnership with OpenAI. Under the agreement, Getty Images will integrate its licensed visual content into ChatGPT's search and discovery experience, marking a pivotal monetization strategy for traditional content providers in the AI era. This collaboration enables Getty Images' extensive content library to reach broader audiences through AI platforms, creating incremental value for its millions of high-quality archived images. Market response has been overwhelmingly positive, with analysts maintaining consensus buy ratings and an average price target of $3.92. Notably, Wedbush maintains an outperform rating with a $7 price target. Short interest declined from 17.36 million to 16.03 million shares, reflecting improving market sentiment. CEO Craig Peters emphasized that high-quality licensed visual content will enhance the reliability of AI-driven search capabilities, positioning the company to capitalize on artificial intelligence opportunities and opening new growth avenues in the evolving digital landscape.

Definium Therapeutics, Inc.: Overnight gain 49.8%, Surges Amid Breakthrough Phase 3 Trial Results for Depression Treatment

Company profile missing.

Definium Therapeutics, Inc. (DFTX) shares surged 49.8% following breakthrough results from its pivotal Phase 3 "Emerge" clinical trial of DT120 orally disintegrating tablet for major depressive disorder. The study successfully achieved its primary endpoint and all key secondary efficacy endpoints. Trial data demonstrated statistically significant improvement versus placebo on MADRS total score at week 6, with placebo-adjusted baseline change of 8.1 points, sustained at 7.3 points through week 12. Notably, DT120 showed rapid onset of action with significant improvement observed as early as week 1, offering faster relief compared to existing antidepressants. The treatment exhibited favorable safety profile, with 99% of treatment-related adverse events being mild-to-moderate and transient, with no serious adverse events reported. The CEO highlighted these unprecedented differentiated efficacy results support a novel approach to treating major depressive disorder, driving the substantial stock rally.

Apogee Therapeutics, Inc.: Overnight gain 46.7%, Surges Amid AbbVie Acquisition Deal for Immunology Pipeline

Apogee Therapeutics, Inc. was incorporated in Delaware on June 9, 2023, serving as a holding company with full ownership of Apogee Therapeutics, LLC and its subsidiaries. The company is positioned as a biotechnology enterprise focused on developing differentiated biologics targeting inflammatory and immunological conditions, including atopic dermatitis and chronic obstructive pulmonary disease, intending to address unmet medical needs in these therapeutic areas. The company's antibody development programs leverage advanced antibody engineering technologies to overcome limitations of existing treatment paradigms through optimized drug half-life characteristics, while building upon well-established mechanisms of action for product development.

AbbVie Announces $10.9 Billion Cash Acquisition of Apogee Therapeutics, Inc. (APGE). Apogee Therapeutics, Inc. (APGE) shares surged following AbbVie's announcement of its approximately $10.9 billion cash acquisition of the company. The deal, priced at $135.11 per share, has received unanimous approval from both companies' boards of directors and is expected to close in Q3 2026. The acquisition centers on Apogee's clinical-stage pipeline, particularly its lead asset zumilokibart (APG777), an extended half-life monoclonal antibody targeting IL-13 for atopic dermatitis treatment. Phase 2 clinical trials demonstrated significant skin clearance in approximately two-thirds of patients. This strategic acquisition will substantially strengthen AbbVie's immunology portfolio and accelerate its respiratory disease treatment initiatives. APGE shares jumped 46.7% in a single trading session following the announcement, bringing year-to-date gains to 75.6%, reflecting strong market approval of this premium-priced transaction.

The Top 10 Daily Gainers in the USA market are listed as follows: